Comparative Effectiveness Research of Electroacupuncture and TENS in Patients With Rheumatoid Arthritis

Overview

The aim of this pilot study is to compare the effectiveness of electroacupuncture or transcutaneous electrical nerve stimulation in reducing the tenderness in the patients with rheumatoid arthritis. The study adopted a pragmatic, randomized, patient-centered approach to investigate the effectiveness of clinical symptoms and quality of life.

Full Title of Study: “Comparative Effectiveness Research of Electroacupuncture and Transcutaneous Electrical Nerve Stimulation in Patients With Rheumatoid Arthritis: A Pragmatic Randomized Clinical Trial”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Single (Outcomes Assessor)
  • Study Primary Completion Date: September 30, 2025

Detailed Description

A total of 80 volunteers of patients with rheumatoid arthritis will be recruited from the Chinese medicine or Western medicine clinics in China Medical University Hospital and Dalin Tzu-Chi Hospital. These patients will be randomized to receive electroacupuncture (40 participants) or transcutaneous electrical nerve stimulation (40 participants) treatment two sessions per week and for 10 treatments in total. The investigators expect that electroacupuncture or transcutaneous electrical nerve stimulation can reduce the severity of pain in the patients with rheumatoid arthritis. The effectiveness of electroacupuncture or transcutaneous electrical nerve stimulation can be detected by visual analogue scale, simplified disease activity index, and disease activity score and be used to improve the clinical symptoms and quality of life.

Interventions

  • Device: electroacupuncture
    • Electroacupuncture used to reduce the inflammation was proved previously.
  • Device: TENS
    • Patients who unlike needles would like to choose TENS as treatment for pain relief.

Arms, Groups and Cohorts

  • Experimental: electroacupuncture
    • The needles remained in situ for 30 minutes, during which time the acupuncturist returned to stimulate the needles once to re-elicit the de qi sensation. Participants have 2 sessions per week, with total 5 weeks and 10 sessions. The body points included LI4, LI11, SP6 and ST36. The individual specific points protocol are as follows: GB20, TE5, SP10, GB34, LV3, ba xie, ba fen, Ashi). The acupuncture protocol consists of the body points and some of the individual specific points depending on subjects’ condition.
  • Experimental: Transcutaneous electrical nerve stimulation
    • The protocol consisted of first swabbing all points with alcohol, then pads of TENS were sticked on the proper location of acupoints included LI4, LI11, SP6 and ST36. Electrical output of one channel was administered to the surface of body via a combination of two pads. LI4 and LI11, ST36 and SP6 are combination of acupoints, respectively. Participants had 2 sessions per week, with total 5 weeks and 10 sessions. Each session lasted 30 minutes.

Clinical Trial Outcome Measures

Primary Measures

  • Morning stiffness(scoring range 0~10 and lasting time : min/day)
    • Time Frame: baseline, week 5, and week 9
    • Changes from baseline to end of intervention and 4 weeks after intervention completed

Secondary Measures

  • Simplified disease activity index (scoring range 0.0 ~ 86.0)
    • Time Frame: baseline, week 5, and week 9
    • Changes from baseline to end of intervention and 4 weeks after intervention completed
  • Disease Activity Score 28 (scoring range 0.0 ~ 9.4)
    • Time Frame: baseline, week 5, and week 9
    • Changes from baseline to end of intervention and 4 weeks after intervention completed
  • Erythrocyte sedimentation rate
    • Time Frame: baseline, week 5, and week 9
    • Changes from baseline to end of intervention and 4 weeks after intervention completed
  • Clinical Disease Activity Index (scoring range 0.0 ~ 76.0)
    • Time Frame: baseline, week 5, and week 9
    • Changes from baseline to end of intervention and 4 weeks after intervention completed
  • Pain Visual Analogue Scale (scoring range 0 ~ 10)
    • Time Frame: baseline, week 5, and week 9
    • Changes from baseline to end of intervention and 4 weeks after intervention completed
  • C-reactive protein
    • Time Frame: baseline, week 5, and week 9
    • Changes from baseline to end of intervention and 4 weeks after intervention completed

Participating in This Clinical Trial

Inclusion Criteria

  • 20-70 years old – Met the American College of Rheumatology criteria (2010) for RA – Classification of X-ray : Stage I~III – The participants' RA medication regimen (DMARD, NSAID, steroid)were eligible if they were on a stable dose for at least 3 months before entry into and throughout the study. – All patients were instructed not to make any changes in their background therapies during the study. – Intra-articular or pulse steroid were not permitted during the study Exclusion Criteria:

  • Be treated with biological agents, such as antagonist of TNF-alpha, IL-6, Jak, and CD20 mono antibody in the last 3 months – Having history of serious drug allergy – Pregnancy or breastfeeding – Bleeding or coagulation disorders – Localized skin infections – Uncontrolled or ill-controlled blood pressure with diastolic pressure≥110 mmHg – Any other acupuncture treatment or herbal medication for RA within 2 weeks before screening – needle phobia – Intra-articular corticosteroid or pulse steroid within 4 weeks preceding the study – Any severe chronic or uncontrolled comorbid disease

Gender Eligibility: All

Minimum Age: 20 Years

Maximum Age: 70 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • China Medical University Hospital
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Hung-Rong Yen, M.D. Ph.D., Principal Investigator, China Medical University Hospital
  • Overall Contact(s)
    • Hung-Rong Yen, M.D. Ph.D., 886-4-22052121, hungrongyen@gmail.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.